Emsella® for pelvic strength
EMSELLA® Pelvic Floor Support During Weight Loss
Lose Weight Without Overlooking Your Pelvic Health
Weight loss can improve blood sugar, mobility, energy, joint health, and overall well-being. It can also reduce the pressure placed on the bladder and pelvic floor.
But the number on the scale is only one part of the transformation.
As the body changes—particularly during rapid or medication-supported weight loss—muscle health, bowel function, core stability, hydration, nutrition, and pelvic-floor strength deserve attention. Some patients become more aware of leakage, urgency, pelvic weakness, or reduced support that may have been present before weight loss or may become more noticeable as their body composition changes.
EMSELLA® is a noninvasive treatment that stimulates and strengthens weak pelvic-floor muscles. It may be incorporated into a physician-directed weight-management program to support bladder control, pelvic strength, and confidence throughout the weight-loss journey.
Weight and the Pelvic Floor Are Connected
The pelvic floor forms the muscular base of the pelvis. It helps support the bladder, uterus, rectum, and other pelvic structures while contributing to urinary control, bowel control, and sexual function.
Carrying excess weight can increase pressure within the abdomen and place additional demand on the pelvic-floor muscles and the tissues supporting the bladder and urethra. Overweight and obesity are recognized, modifiable risk factors for urinary incontinence, particularly in women.
Pelvic-floor symptoms associated with excess weight may include:
Leakage with coughing, sneezing, laughing, or exercise
A sudden urge to urinate
Difficulty reaching the bathroom in time
Increased urinary frequency
Pelvic pressure or heaviness
Reduced confidence during movement or exercise
Bowel-control concerns
Difficulty correctly activating the pelvic-floor muscles
These symptoms should be evaluated rather than automatically attributed to weight alone.
Weight Loss Often Improves Urinary Leakage
Weight loss is generally beneficial for bladder health.
In a randomized clinical trial involving 338 overweight or obese women with urinary incontinence, an intensive six-month weight-loss program produced a greater reduction in weekly incontinence episodes than a structured education program. The study supports weight reduction as an important treatment strategy for urinary leakage in appropriate patients.
The National Institute of Diabetes and Digestive and Kidney Diseases also advises that losing weight may improve urinary incontinence and that maintaining a healthy weight may help prevent bladder-control problems.
EMSELLA® may provide additional muscle support for patients who already have weakness, leakage, or difficulty activating the pelvic floor while they work toward a healthier weight.
Why Pelvic Symptoms May Still Need Attention During Weight Loss
Even when weight reduction decreases abdominal pressure, pelvic symptoms may not disappear completely.
Several factors may influence how the pelvic floor functions during a significant body-composition change.
Preexisting Pelvic-Floor Weakness
Pregnancy, childbirth, menopause, pelvic surgery, chronic coughing, constipation, aging, and previous weight gain may already have weakened the pelvic floor.
Weight loss can reduce one source of pressure without completely restoring muscles that have become weak or poorly coordinated.
Changes in Overall Lean Mass
Intentional weight loss reduces fat mass, but some lean mass may also be lost.
In a body-composition substudy of the SURMOUNT-1 tirzepatide trial, approximately 75% of the weight lost was fat mass and approximately 25% was lean mass. The percentage varies among individuals, and lean mass includes more than skeletal muscle. The study did not specifically measure pelvic-floor muscle loss.
However, the possibility of overall muscle loss reinforces the importance of:
Adequate protein and nutrition
Resistance exercise
Core and pelvic-floor conditioning
Avoiding unnecessarily rapid weight loss
Monitoring strength and physical function
Reduced Activity or Deconditioning
Some patients become less active during periods of nausea, fatigue, reduced food intake, illness, or rapid weight change. Less movement may contribute to generalized deconditioning even while body weight is improving.
Constipation and Straining
Constipation can contribute to temporary urinary incontinence and may increase straining and pelvic-floor symptoms. NIDDK lists constipation among health problems that can cause temporary bladder leakage.
Constipation is also a common adverse effect listed for weight-management medications containing semaglutide or tirzepatide. The current FDA prescribing information for Wegovy® and Zepbound® includes constipation among common gastrointestinal reactions; severe constipation and related complications have also been reported.
Managing hydration, fiber, movement, medication dosing, and bowel habits may therefore be an important part of pelvic wellness during GLP-1 treatment.
GLP-1 Medications and Pelvic-Floor Health
GLP-1–based medications can be highly effective tools for treating obesity and supporting clinically meaningful weight reduction.
Although not currently established as a direct cause of pelvic-floor weakness or urinary incontinence, some aspects of medication-supported weight loss may indirectly influence pelvic symptoms:
Rapid weight change
Reduction in overall lean mass
Constipation or difficult bowel movements
Vomiting or repeated increases in abdominal pressure
Reduced protein intake
Fatigue and decreased resistance exercise
Dehydration
Preexisting weakness becoming more noticeable
What Is EMSELLA®?
EMSELLA® is a prescription medical device that uses noninvasive electromagnetic stimulation to activate the nerves controlling the pelvic-floor muscles.
You remain fully clothed while sitting on the specialized treatment chair. The electromagnetic field produces repeated pelvic-floor muscle contractions intended to rehabilitate weak muscles and improve neuromuscular control.
The FDA-cleared indication includes rehabilitation of weak pelvic musculature and restoration of neuromuscular control for the treatment of urinary incontinence in adult women and men.
EMSELLA® does not cause weight loss and does not directly treat obesity. Its role is to address the pelvic-floor component of your broader health plan.
How EMSELLA® May Support a Weight-Management Program
EMSELLA® may be considered to help:
Strengthen weak pelvic-floor muscles
Improve awareness and activation of the pelvic floor
Reduce selected episodes of urinary leakage
Support return to walking, running, or exercise
Improve confidence during coughing, sneezing, lifting, or jumping
Address weakness that remains as body weight decreases
Complement core-strengthening treatment
Support pelvic health during the transition from active weight loss to maintenance
Strong pelvic-floor muscles provide better support for bladder control than weak muscles. Pelvic-floor muscle training is an established conservative treatment for urinary incontinence.
EMSELLA® may be one option for stimulating these muscles, particularly for patients who have difficulty identifying or consistently contracting them voluntarily.
The Core-to-Floor Weight-Loss Strategy
The pelvic floor does not function independently from the abdomen, diaphragm, back, and hips.
For selected patients, Dr. Eakin may recommend a coordinated Core-to-Floor approach.
EMSELLA® to target the pelvic-floor muscles involved in bladder support and urinary control.
EMSCULPT NEO® to target selected abdominal muscles while also addressing localized abdominal fat. Within a weight-management plan, the focus may be on improving core strength, muscle engagement, and body composition.
Who May Benefit?
An EMSELLA® Weight-Loss Support evaluation may be appropriate if you:
Have urinary leakage while losing weight
Experienced leakage before beginning your weight-management program
Leak with coughing, sneezing, exercise, or lifting
Notice sudden urinary urgency
Avoid exercise because of fear of leaking
Have a history of pregnancy or childbirth
Are navigating perimenopause or menopause
Have difficulty identifying or contracting the pelvic floor
Are using a GLP-1–based medication and experiencing constipation
Have experienced significant or rapid weight loss
Want pelvic-floor support as you become more physically active
Are combining EMSELLA® with EMSCULPT NEO® as part of a Core-to-Floor plan
New urinary symptoms still require evaluation. They should not automatically be attributed to weight loss or medication.
Weight Loss Should Help You Move Forward—Not Hold You Back
A successful weight-management program should support more than a lower number on the scale.
It should help you feel stronger, move more confidently, preserve your independence, and participate in activities without fear of bladder leakage.
EMSELLA® may provide targeted pelvic-floor support while medical weight management, nutrition, resistance exercise, bowel health, and core conditioning address the rest of the journey.
FREQUENTLY ASKED QUESTIONS
-
There is not currently strong evidence that semaglutide, tirzepatide, or other GLP-1–based medications directly weaken the pelvic-floor muscles.
Weight loss may involve some reduction in lean mass, and gastrointestinal effects such as constipation can influence pelvic symptoms. These are reasons to monitor muscle health and bowel function—not reasons to assume that the medication is directly damaging the pelvic floor.
-
Often, yes.
Excess weight can increase abdominal pressure and the likelihood of urinary leakage. Clinical research has shown that behavioral weight reduction can significantly reduce incontinence episodes in overweight and obese women.
However, weakened pelvic floor from long-term pressure of the excess weight may not improve on its own.
-
Weight reduction may decrease pressure on the bladder, but it does not automatically restore muscles that are already weak or poorly coordinated.
EMSELLA® may be considered when leakage or weakness persists during or after weight loss.
-
Constipation can contribute to temporary urinary incontinence and may lead to repeated straining, discomfort, or difficulty coordinating the pelvic floor. Constipation is a recognized adverse effect of both semaglutide and tirzepatide products.
Persistent or severe constipation should be discussed with the clinician managing your medication.
-
No.
EMSELLA® stimulates the pelvic-floor muscles. It does not prevent lean-mass loss throughout the entire body.
Whole-body muscle preservation also requires resistance exercise, adequate protein, appropriate nutrition, and a medically suitable pace of weight reduction.
-
The medication itself does not automatically prevent treatment.
Your overall medical history, hydration, nutritional intake, bowel function, pelvic symptoms, implanted devices, and ability to tolerate treatment must still be reviewed.
-
No.
EMSELLA® does not reduce appetite, burn substantial body fat, or produce meaningful weight loss. It is a pelvic-floor muscle-treatment option for appropriate urinary-incontinence concerns.
-
These symptoms may indicate pelvic-organ prolapse or another condition that requires examination.
EMSELLA® may strengthen muscles but does not reposition pelvic organs or repair stretched supportive tissue.
-
More contractions may not be helpful for an overactive or painful pelvic floor.
Pelvic-floor physical therapy, relaxation strategies, breathing retraining, manual treatment, or specialist evaluation may be recommended first.
-
Treatment may not be appropriate during pregnancy or for patients with certain electronic or metal implants, active infection, recent surgery, unexplained bleeding, significant urinary retention, or another medical contraindication.
A complete medical and device-safety screening is performed before treatment.
